13 August 2018
Visiongain has launched a new pharma report Global Medical Marijuana Market 2017-2027: Chronic Pain, Arthritis, Migraine, Cancer, National Markets, Patent Analysis, Leading Companies
Scientific studies of the extract of marijuana, called cannabinoids, have led to two FDA-approved medications that contain cannabinoid chemicals in pill form. Currently, the two main extract from the marijuana plant that are being used for medical treatments are THC and CBD. THC increases appetite and reduces nausea. THC also decrease pain, inflammation, and muscle control problems. CBD is useful in reducing pain and inflammation, controlling epileptic seizures, muscle spasms caused by multiple sclerosis, nausea, poor appetite, weight loss, crohn’s diseases and possibly treating mental illness and addictions.
The lead analyst of the report commented “Medical Marijuana is one the most promising method to treat various kinds of cancer. Moreover, scientists are doing constant research to make medical marijuana more effective. Hence, increasing research in the improvement of medical marijuana and constant development to find new treatment of cancer is one of the main factors driving the growth of this market.
The growing number of states legalizing medical marijuana and increasing demand for cannabis in medical applications are some of the pivotal factors that are expected to propel the demand for medical marijuana over the coming years.”
Leading companies featured in the report include Cara Therapeutics, Inc., Cannabis Sativa, Inc., CannaGrow Holdings, Inc., Aphios Corporation, United Cannabis Corporation, Growblox Sciences, Inc., GreenGro Technologies, Inc., GW Pharmaceutical, PLC., International Consolidated Companies, Inc., Lexaria Biosciences Corp.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The increasing rates of patent expiry lead to a counter-strategy of switching companies from Rx to OTC. In the US, according to the Consumer Healthcare Products Association, approximately 106 ingredients and dosage strengths have undergone a change from Rx to OTC to around 700 OTC products on the market.
23 September 2020
. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.
16 September 2020
Visiongain forecasts a continuing growth in global market, submarket and product sales as human vaccines drive pharmaceutical business sales. New key players and technological progress will enter the industry, leading to an increase in the market size of the world market for human vaccines in general.
14 September 2020
The global ophthalmic ultrasound systems market is driven by factors such as the increasing prevalence of ocular disorders and diseases, adoption of novel ophthalmic technologies, rising focus on research & development, and growing health awareness amongst the population.